Medical Condition News

RSS

Pathway describes how alpha hydroxyl acids cause skin exfoliation

A team of investigators from UC Davis and Peking University have discovered a mechanism that may explain how alpha hydroxyl acids (AHAs) -- the key ingredient in cosmetic chemical peels and wrinkle-reducing creams -- work to enhance skin appearance. An understanding of the underlying process may lead to better cosmetic formulations as well as have medical applications.

14 Aug 2012

Eating egg yolks accelerates atherosclerosis in a manner similar to smoking

Newly published research led by Dr. David Spence of Western University, Canada, shows that eating egg yolks accelerates atherosclerosis in a manner similar to smoking cigarettes.

14 Aug 2012

Researchers identify molecular pathway by which Notch regulates cell proliferation in lung cancer

Lung cancer is one of the most aggressive types of cancer and the most common cause of death from this disease worldwide. Despite the progress in the molecular biology of lung cancer achieved in recent years, the mechanisms used by tumor cells to grow and spread throughout the body are not yet completely understood. This lack of information is responsible for the limited range of available therapeutic possibilities and their undesirable side effects.

14 Aug 2012

FDA extends PDUFA target action date for review of Santarus' UCERIS NDA

Santarus, Inc. today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the review of the New Drug Application (NDA) for UCERIS (budesonide) tablets 9 mg for the induction of remission of mild to moderate active ulcerative colitis from October 16, 2012 to January 16, 2013.

14 Aug 2012

BUSM part of Transthyretin Amyloidosis Cardiac Study

Researchers at Boston University School of Medicine (BUSM) have been part of a multicenter observational study called TRACS (Transthyretin Amyloidosis Cardiac Study) to help determine the health significance of a particular gene mutation which is commonly found in Black Americans.

14 Aug 2012

Springer to publish book series in cooperation with The Breast Cancer Research Foundation

Springer will publish a series of books in cooperation with The Breast Cancer Research Foundation (BCRF) starting in 2013. Four books will be published annually, and will be included in the Springer series Advances in Experimental Medicine and Biology.

14 Aug 2012

Health law critically important to women; Expanding Medicaid could spur state education cuts; Misuse of antipsychotics in dementia patients

If we can set aside the political wrangling and focus on the benefits of the Affordable Care Act, what becomes obvious is its critically important impact on women's health. The fact is while women are the primary coordinators of health care for families and comprise the majority of U.S. health-care workers, they also put their own health-care needs behind those of their children. Cost is too often the reason.

13 Aug 2012

FDA approves Intelliject's Auvi-Q for anaphylaxis

Intelliject, Inc. announced that the U.S. Food and Drug Administration approved Auvi-Q (epinephrine injection, USP) for the emergency treatment of life-threatening allergic reactions in people who are at risk or have a history of anaphylaxis. This is the first-and-only compact auto-injector with audio and visual cues that guide patients and caregivers step-by-step through the injection process.

13 Aug 2012

Carnegie Mellon University awarded CURE grant by the Pennsylvania Department of Health

Pennsylvania Department of Health Executive Deputy Secretary Michael Wolf today presented a Commonwealth Universal Research Enhancement Program, or CURE, grant to Carnegie Mellon University. The $983,783 grant will be used for a two-year research project focused on cancer treatment technologies.

13 Aug 2012

CBIS initiates CS-TATI-1 GMP development plan

Cannabis Science (CBIS), a pioneering U.S. Biotech Company developing pharmaceutical to meet global public health challenges is pleased to announce the initiation of GMP development plan for CS-TATI-1 with the initial production of CS-TATI-1 to be performed in Colorado under C-GMP conditions evaluated by the FDA for initial human studies to treat HIV associated Kaposi Sarcoma.

13 Aug 2012

Researchers identify new gene in Cornelia deLange syndrome

Genetics researchers have identified a key gene that, when mutated, causes the rare multisystem disorder Cornelia deLange syndrome (CdLS). By revealing how mutations in the HDAC8 gene disrupt the biology of proteins that control both gene expression and cell division, the research sheds light on this disease, which causes intellectual disability, limb deformations and other disabilities resulting from impairments in early development.

13 Aug 2012

Prestigious $2.5M NIH grant to continue work into creation of artificial salivary glands

A research team at the Helen F. Graham Cancer Center at Christiana Care Health System and the Center for Translational Cancer Research performs a key role in a prestigious National Institutes of Health research project grant of $2.5 million to continue groundbreaking work into the creation of artificial salivary glands.

13 Aug 2012

Twelve states currently have adult obesity rate above 30%

Twelve states currently have an adult obesity rate above 30 percent, according to a new analysis released today by the Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF).

13 Aug 2012

Researchers discover gene mutations linked to spinocerebellar ataxia

A global hunt for the cause of a crippling inherited nerve disorder has found its target. The discovery opens the door for better diagnosis and treatment of this particular disease - but also for better understanding of why nerves in the brain's movement-controlling center die, and how new DNA-mapping techniques can find the causes of other diseases that run in families.

13 Aug 2012

NYU Langone offers chance to participate in lung cancer early detection study

NYU Langone Medical Center is a pioneer in lung cancer screening and offers comprehensive screening for individuals at risk for lung cancer. The NYU Langone Lung Cancer Screening Center is distinguished by its multidisciplinary approach and wealth of experience and is under the direction of the Divisions of Pulmonary Medicine, Thoracic Radiology and Thoracic Surgery.

13 Aug 2012

Latrepirdine demonstrates new potential against neurodegenerative conditions

The second of two studies on latrepirdine, recently published in Molecular Psychiatry, demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep disorders, and other neurodegenerative conditions. An international team led by Mount Sinai School of Medicine scientists found that latrepiridine, known commercially as Dimebon, reduced the level of at least two neurodegeneration-related proteins in mice.

13 Aug 2012

Epigenetic factors involved in treatment-resistance to schizophrenia drugs

Researchers at Mount Sinai School of Medicine may have discovered why certain drugs to treat schizophrenia are ineffective in some patients. Published online in Nature Neuroscience, the research will pave the way for a new class of drugs to help treat this devastating mental illness, which impacts one percent of the world's population, 30 percent of whom do not respond to currently available treatments.

13 Aug 2012

Popular class of diabetes drugs increase risk for bladder cancer

A popular class of diabetes drugs increases patients' risk of bladder cancer, according to a new study published online this month in the Journal of the National Cancer Institute.

13 Aug 2012

ALS risk markedly lower among alcohol consumers

A population-based case-control study of the rare but devastating neurological disease amyotrophic lateral sclerosis (ALS) has shown that the risk of such disease is increased among smokers, as has been shown previously. However, surprisingly, the risk of ALS was found to be markedly lower among consumers of alcohol than among abstainers.

13 Aug 2012

FDA extends PDUFA action date for NPS Gattex NDA

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapeutics for rare gastrointestinal and endocrine disorders, today announced that it has received a communication from the U.S. Food and Drug Administration extending the Prescription Drug User Fee Act action date for its New Drug Application for Gattex (teduglutide) by three months to December 30, 2012.

13 Aug 2012